JP2005531607A5 - - Google Patents

Download PDF

Info

Publication number
JP2005531607A5
JP2005531607A5 JP2004510782A JP2004510782A JP2005531607A5 JP 2005531607 A5 JP2005531607 A5 JP 2005531607A5 JP 2004510782 A JP2004510782 A JP 2004510782A JP 2004510782 A JP2004510782 A JP 2004510782A JP 2005531607 A5 JP2005531607 A5 JP 2005531607A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
group
heteroaryl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004510782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005531607A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/017518 external-priority patent/WO2003103663A2/en
Publication of JP2005531607A publication Critical patent/JP2005531607A/ja
Publication of JP2005531607A5 publication Critical patent/JP2005531607A5/ja
Withdrawn legal-status Critical Current

Links

JP2004510782A 2002-06-05 2003-06-04 キナーゼ阻害剤として置換ピロリン Withdrawn JP2005531607A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38600202P 2002-06-05 2002-06-05
PCT/US2003/017518 WO2003103663A2 (en) 2002-06-05 2003-06-04 Substituted pyrrolines as kinase inhibitors

Publications (2)

Publication Number Publication Date
JP2005531607A JP2005531607A (ja) 2005-10-20
JP2005531607A5 true JP2005531607A5 (enExample) 2006-06-29

Family

ID=29736129

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004510782A Withdrawn JP2005531607A (ja) 2002-06-05 2003-06-04 キナーゼ阻害剤として置換ピロリン

Country Status (9)

Country Link
US (4) US7232906B2 (enExample)
EP (1) EP1513520B1 (enExample)
JP (1) JP2005531607A (enExample)
AT (1) ATE409035T1 (enExample)
AU (1) AU2003240517A1 (enExample)
CA (1) CA2488798A1 (enExample)
DE (1) DE60323749D1 (enExample)
ES (1) ES2312785T3 (enExample)
WO (1) WO2003103663A2 (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20031594A3 (cs) 2000-12-08 2004-06-16 Ortho-Mcneil Pharmaceutical, Inc. Pyrrolinové sloučeniny substituované indazolylovou skupinou jako inhibitory kinázy
JP2005529918A (ja) * 2002-05-08 2005-10-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換されたピロリンキナーゼ阻害剤
AU2003240517A1 (en) * 2002-06-05 2003-12-22 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
CA2520590A1 (en) * 2003-03-27 2004-11-04 Janssen Pharmaceutica, N.V. Substituted pyrroline kinase inhibitors
US7439363B2 (en) * 2003-06-13 2008-10-21 Janssen Parmaceutica N.V. Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors
DE602005005787T2 (de) * 2004-01-19 2009-04-30 Novartis Ag Indolylmaleimidderivate
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
US8771754B2 (en) * 2004-09-17 2014-07-08 Vanderbilt University Use of GSK3 inhibitors in combination with radiation therapies
CA2589127C (en) * 2004-12-08 2013-02-05 Johannes Gutenberg-Universitat Mainz 3-(indolyl)-4-arylmaleimide derivatives and their use as angiogenesis inhibitors
WO2006117212A2 (en) 2005-05-04 2006-11-09 Develogen Aktiengesellschaft Use of gsk-3 inhibitors for preventing and treating pancreatic autoimmune disorders
JP2009501172A (ja) 2005-07-11 2009-01-15 ノバルティス アクチエンゲゼルシャフト インドリルマレイミド誘導体
AU2006282896A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
CA2624378A1 (en) * 2005-09-29 2007-04-12 Janssen Pharmaceutica N.V. Macroheterocylic compounds as kinase inhibitors
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
JP2009513672A (ja) 2005-10-31 2009-04-02 ブレインセルス,インコーポレイティド 神経発生のgaba受容体媒介調節
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2377531A2 (en) 2006-05-09 2011-10-19 Braincells, Inc. Neurogenesis by modulating angiotensin
AU2007286817A1 (en) * 2006-08-23 2008-02-28 Novartis Ag Use of PKC inhibitors in particular indolylmaleimide derivatives in ocular diseases
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US8193236B2 (en) 2006-12-19 2012-06-05 Novartis Ag Indolylmaleimide derivatives processes for their production and pharmaceutical compositions
ATE535241T1 (de) * 2007-12-05 2011-12-15 Univ Mainz Johannes Gutenberg Verwendung von 3-(indolyl)- oder 3-(azaindolyl)-4-arylmaleimid-derivaten bei der behandlung von leukämie
FR2927075A1 (fr) * 2008-02-04 2009-08-07 Centre Nat Rech Scient Molecules comprenant un squelette bis-(heteroaryl)maleimide, et leur utilisation dans l'inhibition d'enzymes
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EP2343291A1 (en) 2009-12-18 2011-07-13 Johannes Gutenberg-Universität Mainz 3-(Indolyl)- or 3-(Azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
EP2338486A1 (en) 2009-12-18 2011-06-29 Johannes Gutenberg-Universität Mainz 3-(indolyl)- or 3-(azaindolyl)-4-arylmaleimide derivatives for use in the treatment of colon and gastric adenocarcinoma
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase
EP2474541A1 (en) * 2010-12-23 2012-07-11 Johannes- Gutenberg-Universität Mainz Conjugated 3-(indolyl)- and 3-(azaindolyl)-4-arylmaleimide compounds and their use in tumor treatment
WO2014090398A1 (en) * 2012-12-10 2014-06-19 Centogene Ag Use of maleimide derivatives for preventing and treating leukemia
EP2928465B1 (en) * 2012-12-10 2020-11-18 Centogene GmbH Use of maleimide derivatives for preventing and treating cancer
EP3187495A1 (en) 2015-12-30 2017-07-05 Johannes Gutenberg-Universität Mainz 3-(5-fluoroindolyl)-4-arylmaleimide compounds and their use in tumor treatment
TWI833819B (zh) 2018-10-05 2024-03-01 美商安尼波那生物公司 用於治療與apj受體活性相關的病狀的化合物及組成物
AU2020218366A1 (en) 2019-02-08 2021-09-16 Frequency Therapeutics, Inc. Valproic acid compounds and Wnt agonists for treating ear disorders

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ280738B6 (cs) * 1988-02-10 1996-04-17 F. Hoffmann - La Roche And Co., Aktiengesellschaft Substituované pyrroly, jejich použití pro výrobu léčiv a léčiva na jejich bázi
GB8904161D0 (en) 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
ATE456367T1 (de) 1993-12-23 2010-02-15 Lilly Co Eli Proteinkinase c inhibitoren
BR9710648A (pt) 1996-03-20 1999-08-17 Lilly Co Eli S¡ntese de indolilmaleimidas
SE9603283D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
EP1057484A4 (en) 1998-02-23 2002-11-20 Sagami Chem Res INHIBITORS OF CELL DEATH
AU4929999A (en) 1998-07-30 2000-02-21 Japan Tobacco Inc. Disubstituted maleimide compounds and medicinal utilization thereof
DE69922526T2 (de) 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
HUP0301431A2 (hu) * 2000-07-27 2003-08-28 F. Hoffmann-La Roche Ag. 3-Indolil-4-fenil-1H-pirrol-2,5-dion-származékok, mint glikogén szintáz kináz-3béta inhibitorok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
BRPI0115193B1 (pt) * 2000-11-07 2016-08-09 Novartis Ag derivados de indolilmaleimida, processo para preparação dos mesmos, bem como composição farmacêutica que os compreende
CZ20031594A3 (cs) 2000-12-08 2004-06-16 Ortho-Mcneil Pharmaceutical, Inc. Pyrrolinové sloučeniny substituované indazolylovou skupinou jako inhibitory kinázy
JP2005529918A (ja) 2002-05-08 2005-10-06 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換されたピロリンキナーゼ阻害剤
AU2003240517A1 (en) * 2002-06-05 2003-12-22 Janssen Pharmaceutica N.V. Substituted pyrrolines as kinase inhibitors
WO2003104222A1 (en) 2002-06-05 2003-12-18 Janssen Pharmaceutica N.V. Bisindolyl-maleimid derivatives as kinase inhibitors
CA2520590A1 (en) 2003-03-27 2004-11-04 Janssen Pharmaceutica, N.V. Substituted pyrroline kinase inhibitors
US7439363B2 (en) 2003-06-13 2008-10-21 Janssen Parmaceutica N.V. Substituted indazoly(indoly)maleimide derivatives as kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2005531607A5 (enExample)
JP5269758B2 (ja) 代謝性炎症によって媒介される疾患を処置するためのチアゾリジンジオン類似体
JP2004516314A5 (enExample)
WO2009063202A2 (en) Use of crth2 antagonist compounds
JP2005531609A5 (enExample)
WO2009063215A2 (en) Use of crth2 antagonist compounds
JP2005506352A5 (enExample)
RU2011108026A (ru) Комбинированная терапия туберкулеза
JP2013514368A (ja) 神経変性疾患を処置するための、ppar温存チアゾリジンジオンおよび組み合わせ物
TW200522952A (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
CA2563302A1 (en) Combinations of glycopyrrolate and beta2 adrenoceptor agonists
JP2007517807A5 (enExample)
CN104203936A (zh) 金属酶抑制剂化合物
JP2008509187A5 (enExample)
RU2004100302A (ru) Амиды антраниловой кислоты с гетероарилсульфонильной боковой цепью, способ их получения, их применение в качестве лекарственного или диагностического средства, а также содержащие их фармацевтические композиции
CA2554049A1 (en) Quinoline derivatives for use as mycobacterial inhibitors
JP2013532729A5 (enExample)
TW200927129A (en) Organic compounds
JP2002519425A5 (enExample)
JP2009513713A5 (enExample)
RU2014115290A (ru) Производные 1-фенил 2-пиридинилалкиловых спиртов в качестве ингибиторов
JP2008534453A (ja) 再灌流傷害および再灌流障害の処置のための置換2−チオ−3,5−ジシアノ−4−フェニル−6−アミノピリジンの使用
RU2007130144A (ru) Гетероциклические соединения в качестве антагонистов cccr2b
WO2006060109B1 (en) 2-aminopyridine compounds useful as beta-secretase inhibitors for the treatment of alzheimer's disease
WO2002060423A3 (en) Substituted carbostyril derivatives as 5-ht1a receptor subtype agonists